Parkinson's Disease Treatment Pipeline is Likely to Meet Many Unmet Needs, says GBI Research

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE GBI Research

LONDON, January 12, 2016 

The treatment pipeline for Parkinson's disease offers a markedly more promising landscape from the current market, says GBI Research.

Analysis from business intelligence provider GBI Research - Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation - states that the current Parkinson's disease treatment market relies on neuromodulators, and although symptoms may be eased, there is not an agent that has demonstrated neuroprotective properties to prevent or at least significantly slow neuronal cell death.

The pipeline for Parkinson's disease, however, is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets. For a complimentary sample of this research, please visit the GBI Research website.

Analyst Angel Wong: "The Parkinson's disease treatment pipeline is characterized by a high level of innovation compared to the central nervous system segment and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets being first-in-class.

"While neuromodulators remain dominant in the pipeline, there are a number of targets which address different pathogenic mechanisms underlying neurodegeneration in Parkinson's disease. This demonstrates a shift from traditional symptomatic treatments to disease-modifying therapies."

The analyst adds that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson's disease market in the long term.  

GBI Research's report also states that there are 94 first-in-class products available for strategic consolidations, meaning a vast number of investment opportunities are available for licensing or co-development deals in Parkinson's disease.

Wong explains: "There is substantial focus on early-stage collaboration in Parkinson's disease, especially for first-in-class products. This is predominantly driven by growing unmet needs, the current lack of disease-modifying therapies and a desire for risk-sharing.

"Several first-in-class products have demonstrated promising preclinical evidence, and have significant potential to become game-changing products, representing high-reward investments."

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-161-359-5817

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

©2015 PR Newswire. All Rights Reserved.

http://health.einnews.com/article_detail/305947059/WmcwSRREvk9fzuZh?n=2&code=lAb0qDE0aV13cmUw